Drugs / 64Cu-DOTA-AE105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06474806 | Jun 2024 → Jan 2027 expected | prostate cancer | Curasight | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-04-16 | Curasight | Regulatory Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients curasight.com ↗ |
| 2023-12-18 | Curasight | Regulatory Curasight A/S submits clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients curasight.com ↗ |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-DOTA-AE105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06474806 ↗ |
| Modality | Diagnostic / imaging agent | “The experimental diagnostic agent 64Cu-DOTA-AE105 is a radiopharmaceutical” NCT06474806 ↗ |
| Route | Intravenous | “is injected into the veins” NCT06474806 ↗ |